Bioventus Inc.
BVS
$7.60
$0.010.13%
NASDAQ
| 09/27/2025 | 06/28/2025 | 03/29/2025 | 12/31/2024 | 09/28/2024 | |
|---|---|---|---|---|---|
| Revenue | 138.65M | 147.66M | 123.88M | 153.64M | 138.96M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 138.65M | 147.66M | 123.88M | 153.64M | 138.96M |
| Cost of Revenue | 44.42M | 45.57M | 40.82M | 50.99M | 45.41M |
| Gross Profit | 94.23M | 102.09M | 83.06M | 102.66M | 93.55M |
| SG&A Expenses | 78.64M | 79.10M | 73.48M | 86.53M | 81.43M |
| Depreciation & Amortization | 1.40M | 1.44M | 1.59M | 1.77M | 2.07M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 127.39M | 129.28M | 118.90M | 142.53M | 132.75M |
| Operating Income | 11.27M | 18.38M | 4.97M | 11.11M | 6.21M |
| Income Before Tax | 4.67M | 10.31M | -3.42M | 232.00K | -5.26M |
| Income Tax Expenses | 664.00K | 1.04M | -95.00K | 550.00K | 589.00K |
| Earnings from Continuing Operations | 4.01M | 9.27M | -3.32M | -318.00K | -5.85M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -851.00K | -1.81M | 685.00K | 162.00K | 683.00K |
| Net Income | 3.16M | 7.46M | -2.64M | -156.00K | -5.17M |
| EBIT | 11.27M | 18.38M | 4.97M | 11.11M | 6.21M |
| EBITDA | 22.67M | 30.43M | 16.84M | 15.90M | 18.49M |
| EPS Basic | 0.05 | 0.11 | -0.04 | 0.00 | -0.08 |
| Normalized Basic EPS | 0.03 | 0.07 | -0.02 | 0.03 | -0.02 |
| EPS Diluted | 0.05 | 0.11 | -0.04 | 0.00 | -0.08 |
| Normalized Diluted EPS | 0.03 | 0.07 | -0.02 | 0.03 | -0.02 |
| Average Basic Shares Outstanding | 66.92M | 66.50M | 66.01M | 65.45M | 65.26M |
| Average Diluted Shares Outstanding | 68.84M | 68.54M | 66.01M | 65.45M | 65.26M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |